as fwb evt industry biotechnology founded 1993 headquarters hamburg germany key people werner lanthaler ceo enno spillner cfo dr cord dohrmann cso dr mario polywka coo prof. dr wolfgang plischke chairman of the supervisory board number of employees 1 017 06 2016 slogan research never stops website www.evotec.com evotec ag is a drug discovery and development partnership company providing drug discovery solutions to the pharmaceutical biotechnology and academic sectors as well as to foundations and not for profit organisations . with a pool of highly experienced scientists state of the art technology platforms first class scientific operations and key therapeutic expertise in the areas of neuroscience diabetes and complications of diabetes pain and inflammation oncology and infectious diseases evotec aims to develop best in class and first in class differentiated therapeutics for collaborators or for its own internal pipeline development . evotec founded in 1993 is a publicly listed stock corporation operating under german law . since 2009 the company has been listed in the prime standard at frankfurt stock exchange and is a member of the tecdax index . evotec is headquartered in hamburg germany . in addition to evotec s site in hamburg germany major operating sites exist in abingdon and manchester uk toulouse france g ttingen and munich germany and south san francisco branford and princeton usa . further offices in germany the usa the uk france and japan handle evotec s international business development activities . the evotec group employed 1 017 people at the end of june 2016 . contents 1 history 2 business model & operating segments 3 therapeutics areas 4 pre clinical services 5 management and supervisory board 6 references 7 external links history edit evotec biosystems gmbh was founded in hamburg germany in 1993 . among the founders were nobel laureate manfred eigen karsten henco ulrich aldag freimut leidenberger heinrich schulte rudolf rigler and charles weissmann . in the first years the company established collaborations with international pharma companies like novartis and smithklinebeecham to develop a high throughput screening system evoscreen . 1 in 1999 evotec biosystems went public frankfurt stock exchange evt and merged one year later with the british company oxford asymmetry international plc which offered chemical services for biotech and pharma companies and formed evotec oai in 2005 the name changed to evotec ag 2 . in 2002 the company was divided into two business parts namely discovery and development services and tools and technologies . 3 in this year evotec technologies gmbh was founded . in 2006 evotec technologies was sold to perkin elmer to focus on its core business the discovery and development of new pharmaceutical drugs . 4 in 2008 evotec acquired renovis an us biotech company and was listed on nasdaq . 5 one year later evotec underwent a change in management and strategy . during 2009 evotec implemented its action plan to focus and grow 6 encompassing strict cost cutting and restructuring measures . as a consequence evotec voluntarily delisted its american depository shares from the nasdaq stock market to reduce associated costs and to concentrate its share trading on the tecdax platform which it re entered in 2009 . 7 additionally evotec took over 70 % of indian research support international limited rsipl 8 and a company providing organic synthesis and a zebrafish screening platform from summit corporation . 9 in 2010 evotec acquired develogen ag a company focused on novel therapies for metabolic disorders e.g. diabetes . 10 in 2011 evotec acquired two companies ; kinaxo biotechnologies gmbh a munich based privately owned biotech company . 11 kinaxo s capabilities comprised a combination of technologies improving drug development across the entire pharma value chain . furthermore evotec took over the compound management business from biofocus a subsidiary of the galapagos group . 12 in january 2013 evotec acquired ccs cell culture service gmbh a hamburg based company which supported the cell culture needs of biotech and pharmaceutical companies . 13 in summer 2013 evotec announced the closure of its indian operations . 14 in march 2014 evotec acquired bionamics gmbh an asset management company that focuses on the translation of academic innovations into attractive assets for the biotech and pharma industry . 15 in may 2014 evotec acquired euprotec ltd a uk based specialist contract research organisation leader in anti infective drug discovery services . 16 effective 1 april 2015 evotec and sanofi signed a definitive agreement for major multi component strategic alliance and evotec acquired sanofi s scientific operations and related employees at toulouse site . 17 business model & operating segments edit the company operates and manages its business activities under its two business segments evt execute and evt innovate . evt execute provides stand alone services on a typical fee for service basis or integrated drug discovery on partners targets through a variety of commercial structures including research fees milestones and or royalties . evt innovate develops drug discovery programmes and assets both internally or through academic collaborations . evotec seeks to partner these into collaborations in return for upfront payments and ongoing research payments combined with significant financial upside potential through milestones and royalties . therapeutics areas edit evotec has an expertise in many therapeutic areas including neuroscience oncology immunology and inflammation metabolic diseases and anti infective diseases but also in many other indications in the fields of dermatology haematology ophthalmology rare diseases etc. this expertise has been developed through interactions and contributions in more than 250 collaborations over the past 23 years with life science partners as well as with the acquisition of therapeutic area specific companies like euprotec 18 develogen 19 and the sanofi toulouse site . 20 pre clinical services edit evotec offers services and alliances based on a broad range of integrated capabilities spanning the drug discovery process . services comprise target identification and validation hit identification compound management chemistry & medicinal chemistry drug metabolism and pharmacokinetics research informatics & in silico drug discovery proteomics & metabolomics cell protein and antibody production in vitro pharmacology in vivo pharmacology management and supervisory board edit management dr werner lanthaler chief executive officer enno spillner chief financial officer dr cord dohrmann chief scientific officer dr mario polywka chief operating officer supervisory board prof. dr wolfgang plischke chairman bernd hirsch vice chairman dr claus braestrup prof. dr paul herrling prof. dr iris l w friedrich dr elaine sullivan references edit https www.evotec.com archive en press releases 2002 evotec technologies evoscreen mark iii successfully passed site acceptance testing at novartis 1681 1 http www.scotsman.com news oxford asymmetry merges with evotec 1 838812 https www.evotec.com uploads media library 2 evotec ar09 e web 01 geschuetzt.pdf http www.in pharmatechnologist.com processing perkinelmer buys evotec technologies https www.sec.gov archives edgar data 1118361 000119312507203283 dex991.htm http globenewswire.com news release 2009 03 27 394685 162046 en evotec restructures and implements evotec 2012 action plan to focus and grow.html https www.evotec.com uploads media library 2 evotec ar09 e web 01 geschuetzt.pdf http www.firstwordpharma.com node 912330 tsid 17 axzz4gozpvrlg https media.globenewswire.com newsroom news.html d 164901 http www.growthbusiness.co.uk news and market deals mergers and acquisitions 1269443 evotech acquires develogen.thtml http www.outsourcing pharma.com preclinical research evotec acquires kinaxo expands discovery and development platform http www.marketwired.com press release evotec acquires compound management business from galapagos brux glpg 1520993.htm http globenewswire.com news release 2013 01 03 514347 10016952 en evotec acquires cell culture service gmbh.html https www.evotec.com article en press releases evotec to realign discovery chemistry operations 2417 https globenewswire.com news release 2014 03 24 620483 10073688 en evotec acquires bionamics gmbh to accelerate evt innovate strategy.html http globenewswire.com news release 2014 05 28 639742 10083428 en evotec to establish an anti infectives platform with the acquisition of euprotec ltd.html http www.outsourcing pharma.com clinical development sanofi signs cro evotec to 250m five year research partnership https globenewswire.com news release 2014 03 24 620483 10073688 en evotec acquires bionamics gmbh to accelerate evt innovate strategy.html http www.growthbusiness.co.uk news and market deals mergers and acquisitions 1269443 evotech acquires develogen.thtml http www.outsourcing pharma.com clinical development sanofi signs cro evotec to 250m five year research partnership external links edit official website v t e tecdax companies of germany updated 18.03.2013 adva optical networking aixtron bb biotech bechtle cancom ag carl zeiss meditec dialog semiconductor dr gerwerk drillisch euromicron evotec freenet ag jenoptik kontron lpkf laser & electronics morphosys nordex se pfeiffer vacuum psi ag qiagen qsc ag sartorius ag sma solar technology software ag stratec biomedical systems s ss microtec telef nica germany united internet wirecard xing retrieved from https en.wikipedia.org w index.php title evotec & oldid 735215869 categories biotechnology companies of germanytechnology companies established in 1993pharmaceutical companies established in 1993companies based in hamburghidden categories pages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages deutsch edit links this page was last modified on 19 august 2016 at 08 33 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view